Laura Sepp Lorenzino Intellia Therapeutics, Inc. (NTLA) insider trading activity

Laura Sepp Lorenzino is EVP, Chief Scientific Officer of Intellia Therapeutics, Inc.. Currently has a direct ownership of 86,354 shares of NTLA, which is worth approximately $1.05 Million. The most recent transaction as insider was on Jan 01, 2025, when has been sold 3,500 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 86.4K

5.45% 3M change

86.91% 12M change

Total Value Held $1.05 Million

Laura Sepp-Lorenzino Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 01 2025	BUY Exercise of conversion of derivative security	-	3,500 Added 3.9%	86,354 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	-	37,966 Added 31.68%	81,893 Common Stock
Jan 08 2024	SELL Open market or private sale	$66,020 $29.02 p/Share	2,275 Reduced 4.92%	43,927 Common Stock
Jan 03 2024	SELL Open market or private sale	$162,972 $29.46 p/Share	5,532 Reduced 10.69%	46,202 Common Stock
Jan 01 2024	BUY Exercise of conversion of derivative security	-	3,500 Added 6.34%	51,734 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	29,938 Added 38.63%	47,567 Common Stock
Jan 05 2023	SELL Open market or private sale	$90,077 $38.66 p/Share	2,330 Reduced 11.67%	17,629 Common Stock
Jan 04 2023	SELL Open market or private sale	$93,322 $37.21 p/Share	2,508 Reduced 11.16%	19,959 Common Stock
Jan 01 2023	BUY Exercise of conversion of derivative security	-	3,500 Added 13.48%	22,467 Common Stock
Mar 01 2022	BUY Grant, award, or other acquisition	-	13,816 Added 42.58%	18,631 Common Stock
Jan 01 2022	SELL Open market or private sale	$128,863 $112.25 p/Share	1,148 Reduced 19.25%	4,815 Common Stock
Jan 01 2022	BUY Exercise of conversion of derivative security	-	3,500 Added 36.99%	5,963 Common Stock
Aug 30 2021	SELL Open market or private sale	$15,199,900 $156.7 p/Share	97,000 Reduced 97.59%	2,391 Common Stock
Aug 30 2021	BUY Exercise of conversion of derivative security	$1,341,510 $13.83 p/Share	97,000 Added 49.39%	99,391 Common Stock
Aug 04 2021	SELL Open market or private sale	$3,606,460 $138.71 p/Share	26,000 Reduced 91.58%	2,391 Common Stock
Aug 04 2021	BUY Exercise of conversion of derivative security	$348,400 $13.4 p/Share	26,000 Added 47.8%	28,391 Common Stock

Also insider at

TSHA

Taysha Gene Therapies, Inc. Healthcare